Rilpivirine Hydrochloride/Dolutegravir Sodium

盐酸利匹韦林/多替拉韦钠

Report date: 2022/10/24 09:52:53

Base Information

Drug NameRilpivirine Hydrochloride/Dolutegravir Sodium
Drug Alias NameDolutegravir Sodium/Rilpivirine Hydrochloride复方盐酸利匹韦林多替拉韦钠dolutegravir and rilpivirine盐酸利匹韦林多替拉韦钠Juluca
ClassificationSmall molecules
Mechanisms of ActionHIV integrase inhibitorsReverse transcriptase inhibitors
TargetsHIV integraseReverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2017/11/21
Country/TerritoryBelgiumCanadaUnited States +[16] 
CombinationsYes Rilpivirine HydrochlorideDolutegravir Sodium
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesViiv Healthcare
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcViiv Healthcare BvViiv Healthcare +[5] 
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05AR
Related LinksN/A